194 related articles for article (PubMed ID: 38436589)
21. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
Suzuki SY; Ito K; Ito M; Kawai K
J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
[TBL] [Abstract][Full Text] [Related]
22. Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients.
Anadolu RY; Birol A; Sanli H; Erdem C; Türsen U
Int J Dermatol; 2005 Jul; 44(7):559-65. PubMed ID: 15985024
[TBL] [Abstract][Full Text] [Related]
23. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Wong HK; Mishra A; Hake T; Porcu P
Br J Haematol; 2011 Oct; 155(2):150-66. PubMed ID: 21883142
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
25. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
[TBL] [Abstract][Full Text] [Related]
26. Presence of
Nedoszytko B; Wierzbicki P; Karenko L; Maciejewska-Radomska A; Stachewicz P; Zabłotna M; Gleń J; Väkevä L; Nowicki RJ; Sokołowska-Wojdyło M
Postepy Dermatol Alergol; 2018 Jun; 35(3):274-279. PubMed ID: 30008645
[TBL] [Abstract][Full Text] [Related]
27. New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.
Luna DE; Shinohara MM
Curr Hematol Malig Rep; 2023 Jun; 18(3):83-88. PubMed ID: 37017872
[TBL] [Abstract][Full Text] [Related]
28. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
[TBL] [Abstract][Full Text] [Related]
29. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.
Diamandidou E; Colome-Grimmer M; Fayad L; Duvic M; Kurzrock R
Blood; 1998 Aug; 92(4):1150-9. PubMed ID: 9694702
[TBL] [Abstract][Full Text] [Related]
30. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator.
Ottevanger R; van Beugen S; Evers AWM; Willemze R; Vermeer MH; Quint KD
JAAD Int; 2022 Dec; 9():57-64. PubMed ID: 36147217
[TBL] [Abstract][Full Text] [Related]
31. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
[TBL] [Abstract][Full Text] [Related]
32. A histo-immunopathologic and prognostic study of erythrodermic cutaneous T-cell lymphoma.
Vonderheid EC; Kantor GR; Telang GH; Bujanouskas P; Kadin ME
J Cutan Pathol; 2019 Dec; 46(12):913-924. PubMed ID: 31403211
[TBL] [Abstract][Full Text] [Related]
33. Expression of Granulysin and FOXP3 in Cutaneous T Cell Lymphoma and Sézary Syndrome.
Shareef MM; Elgarhy LH; Wasfy Rel-S
Asian Pac J Cancer Prev; 2015; 16(13):5359-64. PubMed ID: 26225678
[TBL] [Abstract][Full Text] [Related]
34. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas.
Grange F; Hedelin G; Joly P; Beylot-Barry M; D'Incan M; Delaunay M; Vaillant L; Avril MF; Bosq J; Wechsler J; Dalac S; Grosieux C; Franck N; Esteve E; Michel C; Bodemer C; Vergier B; Laroche L; Bagot M
Blood; 1999 Jun; 93(11):3637-42. PubMed ID: 10339469
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and severity of pruritus in cutaneous T cell lymphoma.
Vij A; Duvic M
Int J Dermatol; 2012 Aug; 51(8):930-4. PubMed ID: 22788808
[TBL] [Abstract][Full Text] [Related]
37. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
[TBL] [Abstract][Full Text] [Related]
38. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma.
Lee BN; Duvic M; Tang CK; Bueso-Ramos C; Estrov Z; Reuben JM
Clin Diagn Lab Immunol; 1999 Jan; 6(1):79-84. PubMed ID: 9874668
[TBL] [Abstract][Full Text] [Related]
39. Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature.
Ottevanger R; van Beugen S; Evers AWM; Willemze R; Vermeer MH; Quint KD
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2377-2387. PubMed ID: 34331819
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]